Lupin Limited (BOM:500257)
India · Delayed Price · Currency is INR | Market Cap | 1.00T +13.1% |
| Revenue (ttm) | 299.67B +28.2% |
| Net Income | 55.29B +49.5% |
| EPS | 120.71 +49.4% |
| Shares Out | 457.23M |
| PE Ratio | 18.17 |
| Forward PE | 23.03 |
| Dividend | 18.00 (0.81%) |
| Ex-Dividend Date | Jul 17, 2026 |
| Volume | 30,973 |
| Open | 2,203.50 |
| Previous Close | 2,203.10 |
| Day's Range | 2,186.85 - 2,215.00 |
| 52-Week Range | 1,881.80 - 2,530.00 |
| Beta | 0.18 |
| Analysts | Hold |
| Price Target | 2,513.22 (+14.6%) |
| Earnings Date | Aug 6, 2026 |
About Lupin
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and non... [Read more]
Financial Performance
In fiscal year 2026, Lupin's revenue was 279.58 billion, an increase of 23.12% compared to the previous year's 227.08 billion. Earnings were 53.33 billion, an increase of 62.51%.
Financial StatementsAnalyst Summary
According to 36 analysts, the average rating for 500257 stock is "Hold." The 12-month stock price target is ₹2,513, which is an increase of 14.60% from the latest price.
News
Lupin Secures FDA Approval For Pitolisant Tablets, Generic Of WAKIX; Expects Launch In 2030
(RTTNews) - Lupin Ltd. (LUPIN) on Monday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Pito...
Lupin Transcript: Q1 26/27
Record Q1 revenue and EBITDA growth were driven by strong performance across all geographies, with notable gains in the U.S., India, Europe, and emerging markets. Despite anticipated U.S. headwinds, guidance remains for high single-digit revenue growth and robust margins, supported by a rich pipeline and strategic investments.
Lupin Quarterly report: Q1 2027
Lupin has published its Q1 2027 quarterly earnings report on August 7, 2026.
Lupin Slides: Q1 2027
Lupin has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 7, 2026.
Lupin Transfers Two Oncology Assets To Kaveri Therapeutics
(RTTNews) - Lupin Limited (LUPIN), a pharmaceutical company headquartered in Mumbai, India, has announced the spin-out of two oncology programs—LNP7457 (PRMT5) and LNP8701 (SOS1)—into Kaveri Therapeut...
Lupin receives EIR from U.S. FDA for Somerset facility with VAI classification
Lupin Limited has announced the receipt of an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Somerset, New Jersey facility. The facility…
Lupin receives EMA approval for NaMuscla expansion for paediatric use
Lupin Limited has announced that the European Medicines Agency (EMA) has approved an expansion of the marketing authorisation for NaMuscla. The approval, supported by the Pediatric Investigation Plan,...
Lupin Gets Tentative FDA Nod For Enzalutamide Tablets
(RTTNews) - Lupin Limited (LUPIN) has received tentative approval from the U.S. FDA for its generic Enzalutamide Tablets, marking another step in the company's effort to expand its oncology portfolio ...
Lupin Wins FDA's Tentative Approval For Enzalutamide Tablets Across Multiple Strengths
(RTTNews) - Pharma major Lupin Ltd. announced (NSE: LUPIN) announced Friday that it has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application ...
Lupin receives tentative approval from U.S. FDA for Enzalutamide tablets
Global pharmaceutical company Lupin Limited announced it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Enz...
Lupin launches Azilsartan Medoxomil Tablets in the United States
Global pharmaceutical leader Lupin Limited has announced the launch of Azilsartan Medoxomil Tablets, available in 40mg and 80mg doses, in the United States. This follows the approval from the U.S.…
Lupin collaboraters with Spain’s ERN to launch Luforbec for Asthma and COPD treatment
Pharmaceutical major Lupin Limited has announced a strategic collaboration with LABORATORIOS ERN S.A. for the launch of Luforbec® (beclometasone/formoterol) 100/6 in Spain. The product is a fixed-dose...
Lupin Wins FDA Approval For Ranluspec Biosimilar To Lucentis
(RTTNews) - Lupin Ltd., (NSE: LUPIN) announced that the U.S. FDA has approved Ranluspec (ranibizumab-hkdz), its interchangeable biosimilar to Lucentis (Genentech). The approval covers both vial and pr...
Lupin And Natco Receive FDA Approval For Eribulin Mesylate Injection
(RTTNews) - Lupin Limited (LUPIN) and its alliance partner Natco Pharma Limited announced that the U.S FDA has approved Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection,...
Natco Pharma and Lupin secure U.S. FDA approval for Eribulin Mesylate Injection
Natco Pharma Limited and its alliance partner Lupin Limited have received approval from the United States Food and Drug Administration (U.S. FDA) for Natco’s Abbreviated New Drug Application (ANDA) fo...
Lupin Receives U.S. FDA Approval For Generic Sutab Tablets
(RTTNews) - Lupin Limited announced that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Sodium Sulfate, Magnesium Sulf...
Lupin Secures China Approval For Oseltamivir Oral Suspension, Marking Its Market Debut
(RTTNews) - Lupin Limited (LUPIN) has received regulatory approval in China for its Oseltamivir Phosphate Oral Suspension, marking the company's first-ever product entry into the Chinese pharmaceutica...
Lupin Transcript: Q4 25/26
Record FY 2026 results with 23% revenue and 55% EBITDA growth, driven by strong U.S., India, and emerging market performance. FY 2027 guidance targets high single-digit revenue growth and 25% EBITDA margin, factoring in increased competition and new product launches.
Lupin Quarterly report: Q4 2026
Lupin has published its Q4 2026 quarterly earnings report on May 8, 2026.
Lupin Slides: Q4 2026
Lupin has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 8, 2026.
Lupin Annual report: Q4 2026
Lupin has published its Q4 2026 annual report on May 8, 2026.
Lupin secures USFDA approval for rare disease drug with $337 million opportunity
Lupin Limited has announced that it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Glycerol Phenylbutyrate Oral L...
Lupin launches Dapagliflozin and Metformin Extended-Release Tablets in the U.S. after FDA approval
Indian pharma major Lupin Limited has announced the launch of its Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States, marking another significant step in its expan...
Lupin Receives Tentative U.S. FDA Approval For Sugammadex Injection
(RTTNews) - Lupin Limited (Lupin) has received tentative approval from the U.S. FDA for its generic Sugammadex Injection, available in 200 mg/2 mL and 500 mg/5 mL single-dose vials. The product is a g...
Lupin receives tentative approval from U.S. FDA for Sugammadex Injection
Lupin Limited has announced a significant milestone with the receipt of tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Sugammadex Injection. This approval pe...